PRESS RELEASE: Millipore Corporation’s Re-Branding Underscores Expanded Capabilities

Millipore Corporation’s Re-Branding Underscores Expanded Capabilities and Partnership with Customers

Millipore Foundation Awards $500,000 Research Gift to the Harvard Stem Cell Institute

BILLERICA, Mass. – September 17, 2007 – Millipore Corporation (NYSE:MIL), a Life Science leader providing technologies, tools and services for the bioscience research and biopharmaceutical manufacturing industry, today unveiled its new brand initiative and visual identity. The re-branding affirms Millipore’s transformation from high performance filtration systems provider to leading Life Science corporation, focused on delivering the pioneering technologies and deep expertise necessary for customers to reach their research and scientific goals. Millipore will communicate this perspective in a new corporate tagline that also serves as the cornerstone of the company’s new brand promise: “Advancing Life Science Together™ Research.Development.Production.”

“Millipore is passionate about collaborating with our customers to solve the world’s most challenging human health issues,” said Martin Madaus, Chairman, President and Chief Executive Officer of Millipore. “We intimately understand the needs and ambitions of scientists and engineers, an understanding honed after proudly working with them, side-by-side, for more than 50 years. As we aim to accelerate the entire development process for our customers – from research to discovery all the way to drug production – we are confident that the new Millipore brand look and message will generate greater global awareness of our expanded capabilities and expertise,” he added.

The new visual representation of the brand will appear in the company’s advertising and documentation, and on its products and packaging. A newly re-branded Millipore website will also be launched later this fall, featuring improved functionality, a robust search engine and additional tools that will make it even easier to do business with Millipore.

With leadership comes a responsibility to give back to the community, which is why the company established the Millipore Foundation more than 20 years ago. Today, to further promote innovation and research in the Life Science industry, Millipore also announced a $500,000 research gift made through the Millipore Foundation to the Harvard Stem Cell Institute (HSCI). HSCI is a scientific collaborative within Harvard University and its affiliated hospitals seeking to fulfill the promise of stem cell biology as a basis for cures and treatments for a wide range of chronic and medical conditions. Millipore’s gift will support the HSCI Seed Grant Program, which provides early funding for innovative projects in any field of stem cell research. “We are pleased to welcome Massachusetts-based Life Science industry leader Millipore as the first corporate donor to the Harvard Stem Cell Institute Seed Grant Program,” said Brock Reeve, Executive Director of the Harvard Stem Cell Institute. “HSCI and Millipore share a commitment to collaboration, with both entities working tirelessly to shorten the distance between theory and discovery – between the present and future – in continuing to move the Life Science industry forward.”

Millipore’s 6,100 employees around the globe are dedicated to serving as innovative Life Science partners with their customers, while tapping the industry’s enormous potential to transform scientific understanding and ultimately improve the quality of human life.

About Millipore – Advancing Life Science Together™
Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 6,100 employees in 47 countries worldwide. Advancing Life Science Together™ For more information visit: http://www.millipore.com/corporate/pressroom.nsf/docs/press_kits.


About The Harvard Stem Cell Institute (HSCI)

The Harvard Stem Cell Institute (HSCI) is a scientific collaborative established in 2004 to fulfill the promise of stem cell biology as the basis for cures and treatments for a wide range of chronic, life-threatening medical conditions. In addition to its scientific work, the Harvard Stem Cell Institute has programs focused on the ethical and legal implications of stem cell research, produces a series of lectures and presentations to help inform the public, has a summer research program for college students, and helps educate high school teachers about stem cell science. Because of the current restrictions on federal funding of embryonic stem cell research, the Harvard Stem Cell Institute depends upon the foresight and generosity of private individuals, foundations, and corporate donors to carry on its work. For more information about the Harvard Stem Cell Institute, please go to http://hsci.harvard.edu. For a slide show, please visit http://hsci.harvard.edu/introduction-video.

Forward Looking Statements:

The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.

Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, the inability to successfully integrate Serologicals or other acquired businesses, failure to achieve design wins into our pharmaceutical and biotechnology customers’ manufacturing design phase for a particular drug; delay, suspension or termination of a customer’s volume production; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of new therapeutics; limitations on cash flow for operations and investment due to increased debt service obligations; the inability to establish and maintain necessary product and process quality levels; reduced demand for cell culture products using bovine serum; the inability to realize the expected benefits of development, marketing, licensing and other alliances; competitive factors such as new membrane or chromatography technology; the inability to achieve anticipated cost benefits of our supply chain initiative; risks relating to our concentration of principal manufacturing operations; the inability to utilize technology in current or planned products due to overriding rights by third parties; potential environmental liabilities; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; exposure to product liability claims; and difficulties inherent in transferring or outsourcing of manufacturing operations. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.

Suggested Articles

Tufts scientists discovered that two anti-seizure drugs can lessen the development of brain defects caused by nicotine exposure in frogs.

Merck will apply its vaccine capabilities to an asset based on Themis’ measles vector platform that is set to enter the clinic this year.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.